ScaleUp Canada, a not-for-profit group connecting investors and companies, has named Pacylex Pharmaceuticals to their Edmonton 50 and Canada 250 lists. Pacylex is honoured to be recognized.

Recent Nature Article highlights potential of using Pacylex NMT inhibitor zelenirstat as an ADC payload. Nature article originally published on April 23, 2026

Pacylex and zelenirstat were featured in recent coverage by Global News. To read and watch their coverage, please find their story here on their website linked in the post.

Biotech Nation featured Pacylex on its September 11th episode: "One Pill to Stop Many Cancers??? Dr. Michael Weickert, CEO, Pacylex Pharmaceuticals" with Dr. Moira Gunn interviewing Pacylex CEO Michael Weickert

CEO Michael Weickert will present Phase 1 safety and efficacy results for zelenirstat in the Orphan Drug indication of Acute Myeloid Leukemia (AML) at the World Orphan Drug Congress USA 2024, Apr 23-25, 2024.

Pacylex initiates a Phase 2a study in colorectal cancer with the first patient dosed with the recommended Phase 2 dose (RP2D). Prolonged Stable Disease of >6 months was observed in 57% (4/7) of the solid tumor patients.

Zelenirstat disrupts oxidative phosphorylation in cancer cells at AACR 2024. This defines a second potential mechanism which may account for early signs of zelenirstat anti-cancer activity in the Phase 1 study

CEO Michael Weickert will attend the upcoming BIO CEO & Investor Conference in NYC and will be meeting with investors regarding the company's Series B funding round.